These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29209222)

  • 1. PK-PD Analysis of Marbofloxacin against
    Lei Z; Liu Q; Yang B; Khaliq H; Cao J; He Q
    Front Pharmacol; 2017; 8():856. PubMed ID: 29209222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin and PK/PD Modeling against
    Lei Z; Liu Q; Xiong J; Yang B; Yang S; Zhu Q; Li K; Zhang S; Cao J; He Q
    Front Pharmacol; 2017; 8():542. PubMed ID: 28871226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PK-PD Integration Modeling and Cutoff Value of Florfenicol against
    Lei Z; Liu Q; Yang S; Yang B; Khaliq H; Li K; Ahmed S; Sajid A; Zhang B; Chen P; Qiu Y; Cao J; He Q
    Front Pharmacol; 2018; 9():2. PubMed ID: 29387013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic modeling of tylosin against Streptococcus suis in pigs.
    Huang L; Zhang H; Li M; Ahmad I; Wang Y; Yuan Z
    BMC Vet Res; 2018 Oct; 14(1):319. PubMed ID: 30355326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation of a rational dosage regimen of ceftiofur hydrochloride oily suspension by pharmacokinetic-pharmacodynamic (PK-PD) model for treatment of swine
    Luo W; Wang D; Qin H; Chen D; Pan Y; Qu W; Huang L; Xie S
    J Vet Sci; 2021 Nov; 22(6):e41. PubMed ID: 34854264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal Regimens and Cutoff Evaluation of Tildipirosin Against
    Lei Z; Liu Q; Qi Y; Yang B; Khaliq H; Xiong J; Moku GK; Ahmed S; Li K; Zhang H; Zhang W; Cao J; He Q
    Front Pharmacol; 2018; 9():765. PubMed ID: 30093860
    [No Abstract]   [Full Text] [Related]  

  • 7. Resistant cutoff values and optimal scheme establishments for florfenicol against Escherichia coli with PK-PD modeling analysis in pigs.
    Lei Z; Liu Q; Khaliq H; Cao J; He Q
    J Vet Pharmacol Ther; 2019 May; 42(3):324-335. PubMed ID: 30801741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dose regimen formulation of tilmicosin against Lawsonia intracellularis in pigs by pharmacokinetic-pharmacodynamic (PK-PD) model.
    Luo W; Qin H; Chen D; Wu M; Meng K; Zhang A; Pan Y; Qu W; Xie S
    Microb Pathog; 2020 Oct; 147():104389. PubMed ID: 32707311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.
    Haritova AM; Rusenova NV; Parvanov PR; Lashev LD; Fink-Gremmels J
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3779-85. PubMed ID: 16940071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling.
    Dorey L; Pelligand L; Lees P
    BMC Vet Res; 2017 Jul; 13(1):209. PubMed ID: 28666426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate.
    Aliabadi FS; Lees P
    J Vet Pharmacol Ther; 2002 Jun; 25(3):161-74. PubMed ID: 12081611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis.
    Sun J; Xiao X; Huang RJ; Yang T; Chen Y; Fang X; Huang T; Zhou YF; Liu YH
    BMC Vet Res; 2015 Dec; 11():293. PubMed ID: 26626889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic testing of marbofloxacin administered as a single injection for the treatment of bovine respiratory disease.
    Vallé M; Schneider M; Galland D; Giboin H; Woehrlé F
    J Vet Pharmacol Ther; 2012 Dec; 35(6):519-28. PubMed ID: 22126438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PK-PD Modeling and Optimal Dosing Regimen of Acetylkitasamycin against
    Huang A; Mao F; Huang L; Xie S; Pan Y; Qu W; Cheng G; Liu Z; Yuan Z; Peng D; Hao H
    Antibiotics (Basel); 2022 Feb; 11(2):. PubMed ID: 35203885
    [No Abstract]   [Full Text] [Related]  

  • 15. The pharmacokinetic-pharmacodynamic modeling and cut-off values of tildipirosin against
    Lei Z; Liu Q; Yang B; Ahmed S; Cao J; He Q
    Oncotarget; 2018 Jan; 9(2):1673-1690. PubMed ID: 29416722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Marbofloxacin in Beagle Dogs After Oral Dosing: Preclinical Safety Evaluation and Comparative Pharmacokinetics of Two Different Tablets.
    Lei Z; Liu Q; Yang B; Khaliq H; Ahmed S; Fan B; Cao J; He Q
    Front Pharmacol; 2018; 9():306. PubMed ID: 29692725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of Susceptibility Breakpoint for Cefquinome against
    Mi K; Li M; Sun L; Hou Y; Zhou K; Hao H; Pan Y; Liu Z; Xie C; Huang L
    Antibiotics (Basel); 2021 Aug; 10(8):. PubMed ID: 34439008
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimizing tylosin dosage for co-infection of
    Lee EB; Abbas MA; Park J; Tassew DD; Park SC
    Front Pharmacol; 2023; 14():1258403. PubMed ID: 37808183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic evaluation of marbofloxacin after intravenous administration at different ages in llama crias, and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation.
    Rubio-Langre S; Aguilar-Sola S; Lorenzutti AM; San Andrés MI; De Lucas JJ; Litterio NJ
    J Vet Pharmacol Ther; 2018 Dec; 41(6):861-870. PubMed ID: 30020535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PK-PD integration and modeling of marbofloxacin in sheep.
    Sidhu PK; Landoni MF; Aliabadi FS; Lees P
    Res Vet Sci; 2010 Feb; 88(1):134-41. PubMed ID: 19523661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.